# Incidence and Timing of Major Arrhythmias in T2D and CKD: **A Real-World Analysis**

<sup>2</sup>iRhythm, San Francisco, CA

## Introduction

- Type 2 diabetes (T2D) is a leading cause of chronic kidney disease (CKD).
- Despite strong links between T2D, CKD, and cardiovascular disease, the incidence and timing of major arrhythmias in this high-risk population remains unclear.
- This study examines the incidence, timing, and risk associations of major arrhythmias in T2D-CKD patients.

### **Methods**

• We analyzed Symphony Integrated Dataverse (2018-2024) claims data on adults with CKD (Stage 1-4) following T2D, assessing arrhythmia occurrence, timing, and metabolic/cardiovascular risk factors.

#### **Table 1: Demographics**

Demographics	T2D → Arrhythmia → CKD (N=397,359)	T2D → CKD → Arrhythmia (N=272,644)						
Age at T2D Index								
18-34	334 (0.1%)	202 (0.1%)						
35-44	2,248 (1%)	1,319 (0.5%)						
45-54	13,108 (3%)	7,705 (3%)						
55-64	55,339 (14%)	31,892 (12%)						
65+	326,330 (82%)	231,526 (85%)						
Sex								
Male	221,293 (56%)	148,382 (54%)						
Female	176,066 (44%)	124,262 (46%)						

## Results

- 670,003 (21%) developed major arrhythmias, primarily atrial fibrillation (AF) (Table 1, Table 2).
- median age 74). In those patients:
- median age 76). Arrhythmia-to-MACE median time: 800 days (2-2,348).
- median age 76). In those patients:
- CKD-to-arrhythmia median time: 355 days (1-2,003).
- Arrhythmia-to-MACE median time: 3 days (0-1,918), CKD-to-MACE median time: 461 days (1-1,998).

#### Table 2: Cardiovascular risk factors within 6 months before or after arrhythmia index date

	T2D → Arrhythmia → CKD (Stage 1-4) (N=397,359)				T2D → CKD (Stage 1-4) → Arrhythmia (N=272,644)				
Number of patients	170,298	2,398	125,983	68,870	31,047	554	21,308	13,791	
Type of arrhythmia	% patients with cardiovascular risk factors	Non-MACE CVD*	Hypertension <sup>†</sup>	MACE <sup>‡</sup>	% patients with cardiovascular risk factors	Non-MACE CVD*	Hypertension <sup>†</sup>	MACE <sup>‡</sup>	
Atrial Fibrillation	86%	86%	86%	88%	78%	80%	77%	79%	
Atrial Flutter	19%	18%	18%	20%	11%	10%	11%	12%	
AV Block first degree	12%	10%	12%	11%	13%	11%	14%	14%	
AV Block other	3%	2%	3%	3%	2%	2%	2%	2%	
AV Block second degree	4%	4%	4%	4%	4%	3%	4%	4%	
AV Block third degree	7%	6%	7%	8%	6%	6%	6%	7%	
Supraventricular Tachycardia	13%	15%	13%	12%	8%	13%	8%	8%	
Ventricular Tachycardia	11%	13%	9%	14%	6%	6%	5%	8%	

\* Non-MACE Cardiovascular Disease (CVD) includes Cardiomyopathy, Myocarditis, and Thromboembolism. † Hypertension includes Essential (primary) hypertension, Secondary hypertension, Intraoperative and postprocedural complications and disorders of circulatory system not elsewhere classified, and Hypertensive crisis & Abnormal blood-pressure reading without diagnosis, # MACE includes Stroke, Myocardial Infarction, Congestive Heart Failure and Acute Coronary Syndrome

## Conclusions

#### Abbreviations

### Pierantonio Russo, MD<sup>1</sup>; Ramaa Nathan, PhD<sup>1</sup>; Vansh Jha, MBA<sup>1</sup>; Harjeet Singh, MBA<sup>1</sup>; Jason Poh, PhD<sup>1</sup>; Ken Boyle, DC<sup>2</sup>; Brent Wright, RN, DrPH<sup>2</sup>; Erik Hendrickson, PhD<sup>2</sup> • <sup>1</sup>EVERSANA LLC, Overland Park, KS;

• Among 3.2M T2D patients with CKD after T2D diagnosis (51% females, median age 73; 49% males, median age 72),

• In 59% of patients with CKD after T2D (Figure 1), arrhythmias preceded CKD (56% males, median age 73; 44% females,

 T2D-to-arrhythmia median time: 488 days (range: 1-2,362); arrhythmia-to-CKD median time: 462 days (1-2,368). • 33,640 (8%) had major adverse cardiovascular events (MACE) after CKD (55% males, median age 76; 45% females,

• In 41% of patients with CKD after T2D (Figure 1), arrhythmias followed CKD (54% males, median age 75; 46% females,

• 45,520 (17%) had MACE on or after arrhythmia (54% males, median age 76; 46% females, median age 76).



#### Arrhythmias are common in T2D-CKD and strongly linked to MACE. Identifying shared mechanisms between T2D, CKD, and arrhythmias requires innovative diagnostic approaches, including continuous ambulatory EKG monitoring to drive early intervention and precision therapies.



#### Presented at the 2025 ADA Scientific Sessions Chicago, IL, USA • June 20 to 23, 2025